Treatment Tapering in JIA With Inactive Disease

Inclusion Criteria: * Patient aged 2 to 17 years and treated with etanercept or tocilizumab or adalimumab, or patient aged 6 to 17 years and treated with abatacept. * Patient with an oligoarticular or polyarticular rheumatoid factor negative JIA * Patient treated with biologic treatment for persistent arthritis according to the marketing authorization. * Patient who achieved inactive disease within two years of treatment with the last biologic agent administered, according to Wallace criteria : no joints with active arthritis, no active uveitis (as defined by the SUN Working Group), ESR or CRP level within normal limits in the laboratory where tested (or, if elevated, not attributable to JIA), physician's global assessment of disease activity score (\< 10/100 visual analogue scale), and duration of morning stiffness \< ou = 15 minutes (within 7 days before the visit). * Patient with inactive disease achieved for less than 12 months. * Patient with stable doses of non-steroidal anti-inflammatory drugs, Methotrexate (maximum 20 mg/m2/week), and other non biologic DMARD for at least one month before inclusion * Patient without steroids or joint injection or live vaccines injection for at least one month. * Signed informed consent by both parents (or legal guardian) and patient's agreement. * Patient affiliated to the National Health Assurance system. Exclusion Criteria: * Patient with systemic form, rheumatoid factor positive, psoriatic or associated with enthesitis related J…